While familiarity with medical terminology will be helpful, knowledge of basic sciences such as molecular biology, genetics and biochemistry will not be necessary to understand the presentations. Although the primary emphasis is on the quality and potential impact of a company's science, attention will also be directed to its leadership, financial resources, alliances and marketing arrangements. Market impact, marketing rights and size of market will be noted. The larger cap biotechnology companies that still represent good values will also be noted, although they are not our focus. To begin receiving of Biotech Insight, just click here and in the new browser window select the subscribe button on the left and then go to the bottom of the page and fill out the subscription form.
Biotech stocks are inherently risky.
The opinions expressed in this newsletter are that of the publisher and do not represent a recommendation to buy or sell. The publisher and its associates or employees may have positions in, and from time to time may buy or sell stock mentioned herein. The content of the newsletter reflects information gathered from reliable sources but the accuracy and completeness cannot be guaranteed. All Rights Reserved. No portion of this letter may be reproduced without the written consent of Garren publishing.